Despite the lack of consensus in the pattern of injections, all manuscripts highlight the importance of prompt recognition and treatment of CNV secondary to SFD and acknowledge that the introduction of anti-VEGF agents was a game changer in the clinical outcome of CNV secondary to SFD.[2,5,6,19,24,90–99]. This evidence concerns the gene VEGFA and Sorsby fundus dystrophy.